ArticleJournal, genetic engineering & biotechnology2025
Bioinformatics and experimental approach identify DNMT3A as a diagnostic marker associated with regulated cell death patterns in psoriasis.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated cell death (RCD) is crucial for the advancement of psoriasis, and providing opportunities as diagnostic indicators and drug sensitivity markers for psoriasis. Nevertheless, there is a lack of exploration regarding a thorough evaluation of RCD and psoriasis. 10 transcriptome datasets from psoriasis patients were retrieved, and then RCD mRNA profile was generated consensus cluster. Subsequently, RCD.score was conducted through machine-learning. Two psoriasis subclasses were identified., each exhibiting distinctive molecular patterns and immunologic landscape. Specifically, patients in molecular cluster B exhibited an immunosuppressive microenvironment, suggesting a non-inflamed immune infiltration phenotype. Then, an RCD.score was conducted, and RCD.score demonstrated promising diagnostic capabilities across 10 datasets. High RCD.score category exhibited a more active immune microenvironment, suggesting an inflamed immune infiltration phenotype. Additionally, scRNA-seq revealed an association between cell types and RCD.score, and RCD.score was higher in the T cells and psoriasis patients. Furthermore, Mendelian randomization screening revealed five genes (CDH6, MTHFR, DNMT3A, SETD1A, and RGS14) as feature genes for psoriasis, and validated in psoriasis patients. Recognizing RCD.score serves as an essential resource for prediction of psoriasis diagnostic, carrying wide-ranging implications for clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.